Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
OncoTherapy Science's revenue for the
six
months ended in Mar. 2026 was 円376.6 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was 円808.5 Mil.
OncoTherapy Science's Revenue per Share for the
six
months ended in Mar. 2026 was 円0.98.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was 円2.45.
Warning Sign:
OncoTherapy Science Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of OncoTherapy Science was -14.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -25.20% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -4.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, OncoTherapy Science's highest 3-Year average Revenue per Share Growth Rate was 75.80% per year. The lowest was -60.90% per year. And the median was 1.60% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
OncoTherapy Science Revenue Related Terms
OncoTherapy Science Revenue Historical Data
* Premium members only.
The historical data trend for OncoTherapy Science's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, OncoTherapy Science's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
OncoTherapy Science Revenue vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Revenue distribution charts can be found below:
* The bar in red indicates where OncoTherapy Science's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円808.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoTherapy Science (TSE:4564) has a Revenue of 円808.5 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on OncoTherapy Science and its competitors.
Is OncoTherapy Science's Revenue too high?
OncoTherapy Science's current Revenue is 円808.5 Mil. Overall, OncoTherapy Science has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does OncoTherapy Science's Revenue compare to VRTX and REGN?
OncoTherapy Science's Revenue of 円808.5 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on OncoTherapy Science and its competitors. OncoTherapy Science's current Revenue is 円808.5 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is OncoTherapy Science stock overvalued right now?
Based on GuruFocus' analysis, OncoTherapy Science (TSE:4564) is currently considered Modestly Overvalued. The stock's GF Value™ is 円16.74, compared to a current price of 円20.00 — trading 19.5% above its estimated fair value. The current Revenue is 円808.5 Mil. OncoTherapy Science's overall GF Score™ is 51/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For OncoTherapy Science (TSE:4564), the current Revenue is 円808.5 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is OncoTherapy Science (TSE:4564) Overvalued in 2026?
Based on GuruFocus' analysis, OncoTherapy Science stock appears to be overvalued.
The current stock price of 円20.00 is trading 19.5% above its estimated GF Value™ of 円16.74.
GuruFocus considers OncoTherapy Science to be Modestly Overvalued.
Key valuation signals for TSE:4564:
Revenue: 円808.5 Mil
GF Value™: 円16.74 vs. price of 円20.00 (19.5% above fair value)
No single metric tells the full story. See the TSE:4564 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.
51GF Score
Get the complete analysis for TSE:4564
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4564 has been successfully added to your 
